Similarly, in patients that underwent CFZ-based combination therapy, intracellular flow cytometry of the CD138+ primary MM cells revealed that complete responders had significantly higher PSMC2 protein levels compared to partial responders [18]. The gene discussed is SDC1; the disease is Miyoshi myopathy.